Senolytic Therapy: Clearing Zombie Cells

Senescent cells - often called "zombie cells" - are cells that have stopped dividing but refuse to die. They accumulate with age and contribute significantly to age-related diseases through the inflammatory molecules they secrete, collectively called the senescence-associated secretory phenotype (SASP).

These zombie cells promote inflammation, degrade tissue structure, and can even induce neighboring healthy cells to become senescent. They're implicated in arthritis, atherosclerosis, neurodegenerative diseases, and even cancer. Clearing them has shown remarkable benefits in animal studies, from improved physical function to extended lifespan.

Senolytic compounds selectively eliminate senescent cells while leaving healthy cells intact. The most studied combination is dasatinib (a cancer drug) plus quercetin (a plant flavonoid). Other promising senolytics include fisetin, piperlongumine, and the BCL-2 inhibitor navitoclax.

Current protocols in longevity medicine typically involve intermittent dosing - taking senolytics for 2-3 consecutive days, then waiting several weeks or months before repeating. This "hit and run" approach clears senescent cells without constant immune system activation. While human trials are ongoing, many longevity-focused physicians and biohackers are already experimenting with these protocols under medical supervision.